Advanced glycation end products and diabetic retinopathy Yashodhara Sharma1

Journal of Ocular Biology, Diseases, and Informatics

Volumn 5, Issue 3-4, 2012, Pages 63-69

  Saxena, Sandeep ^a   Mishra, Arvind ^a   Saxena, Anita ^b   Natu, Shankar Madhav ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

^b SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Advanced glycation end products (AGEs) Hyperglycemia Diabetes mellitus Microvascular disease Retinopathy

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMINOGUANIDINE;

ARTICLE; BIOCHEMISTRY; BLOOD LEVEL; CARBOHYDRATE SYNTHESIS; CHEMICAL STRUCTURE; DIABETES MELLITUS; DIABETIC RETINOPATHY; DIET RESTRICTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYPERGLYCEMIA; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CROSS LINKING; VASCULAR DISEASE;

EID: 84892816606     PISSN: 19368437     EISSN: 19368445     Source Type: Journal    
DOI: 10.1007/s12177-013-9104-7     Document Type: Article

References (108)

1. Singh R, Barden A, Mori T, et al. Advanced glycation endproducts: a review. Diabetologia. 2001;44:129-46.
2. Amos AF, McCarty DI, Zimmet P, et al. The rising global burden of diabetes and its complications: estimates and projections to 2010. Diabet Med. 1997;14(5):S1-S85.
3. Hanssen KF. Blood glucose control and microvascular and macrovascular complications. Diabetes. 1997;46(2):S101-3.
4. Šebeková K, Kupčová V, Schinzel R, et al. Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis-amelioration by liver transplantation. J Hepatol. 2002;36:66-71.
5. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86.
6. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet. 1998;352:837-53.
7. Brownlee M. Glycation and diabetic complications. Diabetes. 1994;43:836-41.
8. Bucala R, Cerami A. Advanced glycation: chemistry, biology and implications in diabetes in aging. Adv Pharmacol. 1992;23:1-34.
9. Hammes HP, Weiss A, Hess S, Araki N, et al. Modification of vitronectin by advanced glycation alters functional properties invitro and the diabetic retina. Lab Invest. 1996;75:325-38.
10. John WG, Lamb EJ. The maillard or browning re-action in diabetes. Eye. 1993;7:230-7.
11. Schmidt AM, Hori O, Brett J, et al. Cellular receptors for advanced glycation end products: implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb. 1994;14:1521-8.
12. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med. 1995;46:223-34.
13. Schmidt AM, Yan SD, Wautier JL, et al. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res. 1999;84:489-97.
14. Schmidt AM, Hasu M, Popov D, et al. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci U S A. 1994;91:8807-11.
15. Fu MX, Wells-Knecht KJ, Blackledge JA, et al. Glycation, glycoxidation, and cross-linking of collagen by glucose: kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes. 1994;43:676-83.
16. Tanaka S, Avigad G, Brodsky B, et al. Glycation induces expansion of the molecular packing of collagen. J Mol Biol. 1988;203:495-505.
17. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes. 1999;48:1-9.
18. Suzuki D, Miyata T, Saotome N, et al. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol. 1999;10:822-32.
19. Lo TW, Westwood ME, McLellan AC, et al. Binding and modification of proteins by methylglyoxal under physiological conditions: a kinetic and mechanistic study with N-α-acetylarginine, N-α-acetylcysteine, and N-α-acetyllysine, and bovine serum albumin. J Biol Chem. 1994;269:32299-305.
20. Frye EB, Degenhardt TP, Thorpe SR, et al. Role of the Maillard react ion in aging of t i ssue proteins. J Biol Chem. 1998;273:18714-9.
21. Ahmed MU, Thorpe SR, Baynes JW. Identification of N-ε- carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem. 1986;261:4889-94.
22. Ledl F, Schleicher E. New aspects of the Maillard reaction in foods and in the human body. Angew Chem Int Ed Engl. 1990;6:565-94.
23. Wells-Knecht KJ, Brinkmann E, Wells-Knecht MC, et al. New biomarkers of Maillard reaction damage to proteins. Nephrol Dial Transplant. 1996;11(5):41-7.
24. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-20.
25. Thornalley JP. Advanced glycation and the development of diabetic complications: unifying the involvement of glucose, methylglyoxal and oxidative stress. Endocrinol Metab. 1996;3:149-66.
26. Cerami C, Founds H, Nicholl I, et al. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci USA. 1997;94:13915-20.
27. Koschinsky T, He CJ, Mitsuhashi T, et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA. 1997;94:6474-9.
28. Nicholl ID, Stitt AW, Moore JE, et al. Increased levels of advanced glycation end products in the lenses and blood vessels of cigarette smokers. Mol Med. 1998;4:594-601.
29. Vlassara H, Cai W, Crandall J, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA. 2002;99:15596-601.
30. Henle T (2003) AGEs in foods: do they play a role in uremia? Kidney Int Suppl S145-S147.
31. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein. Diabetes. 1985;34:938-41.
32. Schmidt AM, Yan SD, Stern DM. The dark side of glucose. Nat Med. 1995;1:1002-4.
33. Garay-Sevilla ME, Regalado JC, Malacara JM, et al. Advanced glycosylation end products in skin, serum, saliva and urine and its association with complications of patients with type 2 diabetes mellitus. J Endocrinol Invest. 2005;28:223-30.
34. Rojas A, Morales MA. Advanced glycation and endothelial functions: a link towards vascular complications in diabetes. Life Sci. 2004;76:715-30.
35. Brownlee M, Vlassara H, Cerami A. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988;318:1315-21.
36. Eble AS, Thorpe SR, Baynes JW. Nonenzymatic glucosylation and glucose-dependent cross-linking of proteins. J Biol Chem. 1983;258:9506-12.
37. Fu MX, Knecht KJ, Thorpe SR, Baynes JW, et al. The role of oxygen in cross-linking and chemical modifications of collagen by glucose. Diabetes. 1992;41:42-8.
38. Sell DR, Lapolla A, Odetti P, et al. Pentosidine formation in skin correlates with severity of complication in individuals with longstanding IDDM. Diabetes. 1992;41:1286-92.
39. Sell DR, Carlson EC, Monnier VM. Differential effects of type 2 (noninsulin-dependent) diabetes mellitus on pentosidine formation in skin and glomerular basement membrane. Diabetes. 1993;40:190-6.
40. Schleicher E, Nerlich A. The role of hyperglycaemia in the development of diabetic complications. Horm Metab Res. 1996;28:367-73.
41. Vlassara H, Brownlee M, Cerami A. High-affinity receptormediated uptake and degradation of glucose modified proteins: a potential mechanism for the removal of senescent macromolecules. Procl Natl Acad Sci USA. 1985;82:5588-92.
42. Higashi T, Sano H, Saishoji T, et al. The receptor for advanced glycation end products mediates the chemotaxis of rabbit smooth muscle cells. Diabetes. 1997;46:463-72.
43. McCance DDG, Dunn JA, et al. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest. 1993;91:2470-8.
44. Beisswenger PJ, Makita Z, Curphey TJ, et al. Formation of immunochemical advanced glycation endproducts precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes. 1995;44:824-9.
45. Chappey O, Dosquet C, Wautier M-P, et al. Advanced glycation end products, oxidant stress and vascular lesions. Eur J Clin Invest. 1997;27:97-108.
46. Vlassara H, Baucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biological, and chemical implications for diabetes and aging. Lab Invest. 1994;70:138-51.
47. Stitt AW, Li YM, Gardiner TA, et al. Advanced glycated endproducts( AGE) co-localise with AGE receptors in the retinal vasculature of diabetic and AGE infused rats. Am J Pathol. 1997;150:523-39.
48. Yamagishi S-C, Yonekura H, Yamamoto Y. Advanced glycation end product driven angiogenesis in vitro. J Biol Chem. 1997;272:8723-30.
49. Monnier VM, Kohn RR, Cerami A. Accelerated age related browning of human in diabetes mellitus. Proc Natl Acad Sci USA. 1984;81:583-7.
50. Doi T, Vlassara H, Kirstein M, et al. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc NatI Acad Sci USA. 1992;89:2873-7.
51. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endotheliumdependent vasodilatation in experimental diabetes. J Clin Invest. 1991;87:432-8.
52. Vlassara H, Fuh H, Makita Z, et al. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci USA. 1992;89:12043-7.
53. Vlassara H, Striker W, Teichberg S, et al. Advanced glycation endproducts induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA. 1994;91:11704-8.
54. Vlassara H, Fuh H, Donnelly T, et al. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med. 1995;1:447-56.
55. Stitt AW, Friedman S, Scher L, et al. Carotid artery advanced glycation end products and their receptors correlate with severity of lesion and with plasma AGE-ApoB levels in non-diabetic patients. FASEB J. 1996;10:A616.
56. Beisswenger PJ, Morre LL, Brinck-Johnsen T, et al. Increased collagen-like pentosidine levels and AGEs in early diabetic nephropathy. J Clin Invest. 1993;92:212-7.
57. Araki N, Ueno N, Chakraharti B, et al. Immunochemical evidence for the presence of advanced glycation end products in human lens proteins and its positive correlation with aging. J Biol Chem. 1992;267:10211-4.
58. Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product Nε-(carboxymethyl) lysine in human tissues in diabetes and aging. J Clin Invest. 1997;99:457-68.
59. Cooper ME, Bonnet F, Oldfield M, et al. Mechanisms of diabetic vasculopathy: an overview. Am J Hypertens. 2001;14(1):475-86.
60. Hammes HP, Alt A, Niwa T, et al. Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia. 1999;42:728-36.
61. Bucala R, Vlassara H. Advanced glycosylation end products in diabetic renal and vascular disease. Am J Kidney Dis. 1995;26:875-88.
62. Makita Z, Bucala R, Rayfield EJ, et al. Reactive glycosylation end products in diabetic uraemia and treatment of renal failure. Lancet. 1994;343:1519-22.
63. Ono Y, Aoki S, Ohnishi K. Increased serum levels of advanced glycation end-products and diabetic complications. Diabetes Res Clin Pract. 1998;41:131-7.
64. Murata T, Nagai R, Ishibashi T. The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia. 1997;40:764-9.
65. Stitt AW. Advanced glycation: an important pathological event in diabetic and age related ocular disease. Br J Ophthalmol. 2001;85:746-53.
66. Stitt AW, Moore JE, Sharkey JA, et al. Advanced glycation end products in vitreous: structural and functional implications for diabetic vitreopathy. Invest Ophthalmol Visual Sci. 1998;39:2517-23.
67. Fosmark DS, Bragadottir R, Stene-Johansen I, et al. Increased vitreous levels of hydroimidazolone in type 2 diabetes patients are associated with retinopathy: a case-control study. Acta Ophthalmol Scand. 2007;85:618-22.
68. Gardiner TA, Anderson HR, Stitt AW, et al. Inhibition of advanced glycation end-products protects against retinal capillary basement membrane expansion during long-term diabetes. J Pathol. 2003;201:328-33.
69. Schalkwijk CG, Ligtvoet N, Twaalfhoven H, et al. Amadori albumin in type 1 diabetic patients: correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries. Diabetes. 1999;48:2446-53.
70. Hammes HP, Brownlee M, Edelstein D, et al. Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia. 1994;37:32-5.
71. Frank RN. On the pathogenesis of diabetic retinopathy. A 1990 update. Ophthalmology. 1991;98:586-93.
72. Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des. 2005;11:2279-99.
73. Yamagishi S, Amano S, Inagaki Y, et al. Advanced glycation end productsinduced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochem Biophys Res Commun. 2002;290:973-8.
74. Yamagishi S, Inagaki Y, Amano S, et al. Pigment epitheliumderived factor protects cultured retinal pericytes from advanced glycation end product induced injury through its antioxidative properties. Biochem Biophys Res Commun. 2002;296:877-82.
75. Yamagishi S, Amano S, Inagaki Y, et al. Beraprost sodium, a prostaglandin I2 analogue, protects against advanced gycation end products-induced injury in cultured retinal pericytes. Mol. Med. 2002;8:546-50.
76. Hammes HP, Lin J, Renner O, et al. Pericytes and the pathogenesis of diabetic retinopathy. Diabetes. 2002;51:3107-12.
77. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-7.
78. Murata T, Ishibashi T, Khalil A, et al. Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. Ophthalmic Res. 1995;27:48-52.
79. Yamagishi S, Nakamura K, Matsui T, et al. Pigment epitheliumderived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem. 2006;281:20213-20.
80. Okamoto T, Yamagishi S, Inagaki Y, et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J. 2002;16:1928-30.
81. Okamoto T, Yamagishi S, Inagaki Y, et al. Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro. Biochem Biophys Res Commun. 2002;297:419-24.
82. Schroder S, Palinski W, Schmid-Schonbein GW. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol. 1991;139:81-100.
83. Moore TC, Moore JE, Kaji Y, et al. The role of advanced glycation end products in retinal microvascular leukostasis. Investig Ophthalmol Vis Sci. 2003;44:4457-64.
84. Lu M, Perez VL, Ma N, et al. VEGF increases retinal vascular ICAM-1 expression in vivo. Investig Ophthalmol Vis Sci. 1999;40:1808-12.
85. Yamagishi S, Matsui T, Nakamura K, et al. Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species. Ophthalmic Res. 2007;40:10-5.
86. Inagaki Y, Yamagishi S, Okamoto T, et al. Pigment epitheliumderived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production inmicrovascular endothelial cells by suppressing intracellular reactive oxygen species generation. Diabetologia. 2003;46:284-7.
87. Mitamura Y, Takeuchi S, Matsuda A, et al. Monocyte chemotactic protein-1 in the vitreous of patients with proliferative diabetic retinopathy. Ophthalmologica. 2001;215:415-8.
88. Hammes HP, Martin S, Federlin K, et al. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA. 1991;88(11):555-58.
89. Chibber R, Molinatti PA, Wong JSK, et al. The effect of aminoguanidine and tolrestat on glucose toxicity in bovine retinal capillary pericytes. Diabetes. 1994;43:758-63.
90. Klein R, Klein BEK, Moss SE, et al. The Wisconsin Epidemiologic study of diabetic retinopathy XIV. Ten-year incidence and progression of diabetic retinopathy. Arch Ophthalmol. 1994;112:1217-28.
91. Chibber R, Molinatti PA, Rosatto N, et al. Toxication of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: relevance to diabetic retinopathy. Diabetologia. 1997;40:156-64.
92. Yamagishi S, Ueda S, Matsui T, et al. Pigment epithelium-derived factor (PEDF) prevents advanced glycation end products (AGEs)-elicited endothelial nitric oxide synthase (eNOS) reduction through its anti-oxidative properties. Protein Pept Lett. 2007;14:832-5.
93. Schmidt AM, Hori O, Chen JX, et al. Advanced glycation end products interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: a potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest. 1995;96:1395-403.
94. Howard EW, Benton R, Ahern-Moore J, et al. Cellular contraction of collagen lattices is inhibited by nonenzymatic glycation. Exp Cell Res. 1996;228:132-7.
95. Haitoglou CS, Tsilibary EC, Brownlee M, et al. Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen. J Biol Chem. 1992;267:12404-7.
96. Koga K, Yamagishi S, Okamoto T, et al. Serum levels of glucosederived advanced glycation end products are associated with the severity of diabetic retinopathy in type 2 diabetic patients without renal dysfunction. Int J Clin Pharmacol Res. 2002;22:13-7.
97. Turk Z, Ljubic S, Turk N, et al. Detection of autoantibodies against glycation end products and AGE immune complexes in serum of patients with diabetes mellitus. Clin Chim Acta. 2001;303:105-15.
98. Sugiyama S, Miyata T, Ueda Y, et al. Plasma levels of pentosidine in diabetic patients: an advanced glycation end product. J Am Soc Nephrol. 1998;9:1681-8.
99. Wagner Z, Wittmann I, Mazak I, et al. N(epsilon)-(carboxymethyl) lysine levels in patients with type 2 diabetes: role of renal function. Am J Kidney Dis. 2001;38:785-91.
100. Dorrian CA, Cathcart S, Clausen J, et al. Factors in human serum interfere with the measurement of advanced glycation end products. Cell Mol Biol. 1998;44:1069-79.
101. Genuth S, Sun W, Cleary P, et al. DCCT Skin Collagen Ancillary Study Group. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes. 2005;54:3103-11.
102. Hartog JW, de Vries AP, Lutgers HL, et al. Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease. Ann NY Acad Sci. 2005;1043:299-307.
103. Bierhaus A, Hofmann MA, Ziegler R, et al. AGE and their interaction with AGE-receptors in vascular disease and diabetes. I. The AGE cononcept. Cardiovasc Res. 1998;37:586-600.
104. Khalifah RG, Baynes JW, Hudson BG. Amadorins: novel postamadori inhibitors of advanced glycation end-products. Biochem and Biophysical Res Commun. 1999;257:251-8.
105. Koschinsky T, He CJ, Mitsuhashi T, et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A. 1997;94:6474-9.
106. Goldberg T, Cai W, Peppa M, et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc. 2004;104:1287-91.
107. Uribarri J, Peppa M, Cai W, et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol. 2003;14:728-31.
108. Yamagishi S, Nakamura K, Matsui T, et al. Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders. Med Hypotheses. 2007;69:666-8.